<DOC>
	<DOCNO>NCT00003735</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness topotecan treat child relapse acute leukemia , acute myeloid leukemia , blast phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy Treating Children With Relapsed Acute Leukemia , Acute Myeloid Leukemia , Blastic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient relapse acute lymphocytic leukemia , acute myeloid leukemia , blastic phase chronic myelogenous leukemia treat oral topotecan . II . Determine toxic effect pharmacokinetics regimen patient . OUTLINE : Patients stratify disease type ( acute lymphocytic leukemia v acute myeloid leukemia ) . Patients receive oral topotecan daily day 1-21 . Courses repeat every 28 day absence blast blood , M3 bone marrow , unacceptable toxicity . Patients follow every 6 month death . PROJECTED ACCRUAL : A total 50 patient ( 25 per stratum ) accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>10-hydroxycamptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven relapse acute lymphocytic leukemia , acute myeloid leukemia , blastic phase chronic myelogenous leukemia Refractory conventional therapy therapy higher priority May concurrent extramedullary relapse except testicular relapse extramedullary site may require concurrent radiotherapy PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 02 Life expectancy : At least 2 month Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 time normal SGOT SGPT less 5 time normal Renal : Creatinine great 1.5 time normal Other : Able take oral liquid medication No GI neuropathy No condition may affect absorption drug No diabetes mellitus Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior bone marrow transplantation ( BMT ) peripheral blood stem cell transplantation ( PBSCT ) allow recover At least 2 week since prior cytokine therapy recover No concurrent immune modulator therapy No concurrent cytokine include interleukin11 , interleukin2 , epoetin alfa Chemotherapy : At least 2 week since prior chemotherapy ( 4 week nitrosoureas ) recover No 3 prior chemotherapy regimens No concurrent chemotherapy Endocrine therapy : No concurrent steroids Radiotherapy : No prior craniospinal radiotherapy Prior total body irradiation allow part BMT PBSCT recover Concurrent radiotherapy localize painful lesion allow Surgery : Not specify Other : No concurrent metoclopramide cisapride maintain motility gastric empty No concurrent H2 antagonists No concurrent proton pump inhibitor No concurrent antacids gastritis , gastroesophageal reflux , ulcer ( gastric duodenal ) No antacid therapy 6 hour 90 minute topotecan administration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
</DOC>